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Infant Outcomes After Maternal Antiretroviral
Exposure in Resource-Limited Settings
WHAT’S KNOWN ON THIS SUBJECT: Information on infant safety
after exposure to maternal antiretroviral regimens during pregnancy
in international clinical trials is lacking. As antiretroviral drugs are
released to populations in resource-limited settings through clinical
trials, it becomes critical to collect pediatric outcome data.
WHAT THIS STUDY ADDS: The study demonstrates the feasibility
of reporting infant outcomes following adult antiretroviral trials
in developing countries, provides HIV-free infant survival and
prospective growth data in association with maternal
parameters, and details morbidity, mortality, and genetic defects
following maternal antiretroviral exposure.
abstract
BACKGROUND AND OBJECTIVE: The impact of maternal antiretrovirals
(ARVs) during pregnancy, labor, and postpartum on infant outcomes
is unclear.
METHODS: Infants born to HIV-infected mothers in ARV studies were
followed for 18 months.
RESULTS: Between June 2006 and December 2008, 236 infants enrolled
from Africa (n = 36), India (n = 47), Thailand (n = 152), and Brazil (n = 1).
Exposure to ARVs in pregnancy included $3 ARVs (10%), zidovudine/
intrapartum ARV (81%), and intrapartum ARV (9%). There were 4 infant
infections (1 in utero, 3 late postpartum) and 4 deaths with 1.8%
mortality (95% confidence interval [CI], 0.1%–3.5%) and 96.4% HIV-1–
free survival (95% CI, 94.0%–98.9%). Birth weight was$2.5 kg in 86%. In
the first 6 months, Indian infants (nonbreastfed) had lowest median
weights and lengths and smallest increases in growth. After 6 months,
African infants had the lowest median weight and weight-for-age
z scores. Infants exposed to highest maternal viral load had the
lowest height and height-for-age z scores. Serious adverse events
occurred in 38% of infants, did not differ by country, and correlated
with less maternal ARV exposure. Clinical diagnoses were seen in 84%
of Thai, 31% of African, and 9% of Indian infants. Congenital defects/
inborn errors of metabolism were seen in 18 (7.6%) infants, of which
17 were Thai (11%: 95% CI, 6.7%–17.0%); none had first trimester ARV
exposure.
CONCLUSIONS: Infant follow-up in large international cohorts is
feasible and provides important safety and HIV transmission data
following maternal ARV exposure. Increased surveillance increases
identification of congenital/inborn errors. Pediatrics 2012;129:
e1525–e1532
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ARTICLE
The use of antiretrovirals (ARVs) in
pregnant HIV-1–infected women has
been highly beneficial to the mother/
infant pair.1–5 Depending on safety and
toxicity profiles, ARVs can be adjusted
before conception or during pregnancy
to reduce potential adverse events. It is
critical to collect data on their safety
during pregnancy and to monitor po-
tential toxicities in infants after expo-
sure to maternal regimens. The AIDS
Clinical Trials Group protocol A5190/
International Maternal Pediatric Adoles-
cent AIDS Clinical Trials Group P1054
was a prospective, observational, cohort
study of infants born to HIV-1–infected
mothers enrolled in National Institutes
of Health (NIH)-sponsored ARV trials in
resource-limited settings. Infants were
enrolled from birth and followed for
18 months. The primary objective was
to assess the safety of infant exposure
to maternal ARV during pregnancy and
postpartum.
METHODS
The study was a prospective, observa-
tional cohort assessing the safety of in
utero, intrapartum, and breast milk ex-
posures to maternal ARVs. The study
population consisted of live-born infants
of HIV-1–infectedwomenenrolled inNIH-
sponsored international trials. Three
ARV treatment studies and 2 ARV pre-
vention of mother-to-child transmission
(PMTCT) study groups participated.
A5175 is a Phase IV randomized trial of
once-daily protease inhibitor and once-
daily nonnucleoside reverse transcrip-
tase inhibitor–containing combinations
for initial treatment of HIV-1–infected
individuals in resource-limited settings
(PEARLS).6 A5208 is a randomized com-
parison of combination therapy to opti-
mize therapy after nevirapine (NVP)
exposure (OCTANE).7 HPTN 052 is a ran-
domized trial to evaluate ARV effective-
ness to prevent sexual HIV transmission
in serodiscordant couples.8 A5207 is
a randomized comparison of 3 ARV
strategies given for 7 or 21 days to re-
duce NVP resistance after single-dose
NVP.9 And P1032 is a randomized study
of zidovudine (ZDV)/didanosine or ZDV/
didanosine/lopinavir-ritonavir to reduce
NVP resistance after single-dose NVP.10
Exposure of infants to ARVs was as-
sessed via maternal ARVs in utero, via
direct administration, and via breast-
feeding. In utero ARV exposure is de-
tailed in Table 1. The degree of exposure
to maternal ARV varied by study and
was categorized as exposure to $3
ARVs during pregnancy;$7 days of ZDV
prophylaxis in utero plus intrapartum
exposure to ARV, or intrapartum expo-
sure to ARV. Direct exposure of infants
to ARVs included single-dose NVP and
single-dose NVP + ZDV. Maternal param-
eters included HIV-1 virus load and CD4
(cluster of differentiation 4 [T4 helper
cell]) counts closest to delivery, medical
history, and clinical status. Infants had
6 study visits over 18 months. Assess-
ments included weight, height, head
circumference, and laboratory evalua-
tions (complete blood counts, liver
function tests, serum chemistries, and
urinalysis). HIV-1 RNA polymerase chain
reaction (PCR) (Roche AmplicorMonitor
Test, Version 1.5, Roche Molecular Di-
agnostics, Pleasanton, CA) was perfor-
med up to 12 months for breastfed
infants and up to 3 months for non-
breastfed infants. HIV-1 antibody en-
zyme immunoassay was performed at
18 months. VDRL/rapid plasma regain
testing was performed at the first visit.
All participating sites were clinical
research centers affiliated with NIH
networks. All mothers provided writ-
ten informed consent. The study was
approved by foreign institutional review
boards and collaborating US institutions.
Statistical analysis was descriptive.
A5190/P1054 was not powered to de-
tect specific differences between rates
of adverse events in ARV study arms.
A 2-sided nominal P value ,.05 was
used to indicate comparisons for ad-
ditional exploration. Comparisons be-
tween groups for continuous variables
used Kruskal-Wallis tests while com-
parisons between categorical varia-
bles usedFisher’s exact test. Comparisons
between groups for safety data used the
log-rank test. Rates were estimated by
using the Kaplan-Meier method with
Greenwood’s confidence intervals (CIs).
RESULTS
From June 2006 to December 2008, 236
infants were enrolled (Table 2), 74%
within the first week of life. The ma-
jority of infants (n = 212) were enrolled
through perinatal studies (P1032 = 151,
A5207 = 61) in which ARV exposure oc-
curred in the third trimester of preg-
nancy and/or intrapartum. Twenty-four
infants were enrolled from adult treat-
ment studies. Within the cohort, 29
(12%) infants were breastfed, all in
African countries. Table 3 demonstrates
the degree of exposure to maternal ARV
and infant ARV exposure. Of 236 infants,
232 (98%) completed 6 months and 222
TABLE 1 Fetal/Infant Exposure to Maternal ARVs In Utero, Intrapartum and Postpartum by Parent
Protocol for Infants Enrolled in A5190/P1054
Maternal ARV Treatment Studies PMTCT Studies
A5175 n = 8 A5208 n = 3 HPTN 052 n = 13 A5207 n = 61 P1032 n = 151
First trimester $3 ARVs $3 ARVs $3 ARVs None None
Second trimester $3 ARVs $3 ARVs $3 ARVs None None
Third trimester $3 ARVs $3 ARVs $3 ARVs ZDV ZDV
Intrapartum $3 ARVs $3 ARVs $3 ARVs sd-NVP + 2 ARVs sd-NVP + 2–3 ARVs
Postpartuma $3 ARVs $3 ARVs $3 ARVsb Possiblec None
ARVs, $3 or more maternal ARVs in combination; sd-NVP + 2–3, single-dose NVP and 2–3 ARVs.
a Postpartum exposure via breastfeeding occurred only in African sites.
b Women enrolled in HPTN 052 received combination ARV postpartum only if lower CD4 threshold.
c Exposure to $2 ARVs within the first month of life only.
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(94%) completed 18 months of follow-
up. Four (1.8%) infants died and 10 (4.2%)
were lost to follow-up. The last subject
completed follow-up in May 2010.
Regarding maternal parameters near
the time of delivery, most mothers had
high CD4 cell counts; 100 (42%) had CD4
cell counts .500 cells/mm3, 77 (33%)
had CD4 counts between 350 and 500
cells/mm3, and 59 (25%) had counts
between 200 and 350 cells/mm3 (range,
218–1233 cells/mm3). Maternal virus
load near delivery was,400 copies/mL
of HIV RNA in 28% of mothers, ,1000
copies/mL in 39%, between 1000 and
10 000 copies/mL in 36%, between 10 000
and 100 000 copies/mL in 23%, and
.100 000 copies/mL in 2%. Fifty-four
percent of women with CD4 cell counts
$500 had viral load ,1000; conversely,
39% of women in the 200 to 349 cells/
mm3 CD4 cell stratum had viral loads
$10 000 copies/mL. Ninety-two percent
ofwomen (22 of 24) on regimenswith$3
ARVs had viral loads ,1000 copies/mL,
comparedwith 36% of women (68 of 191)
who received antepartum ZDV and intra-
partum ARV and 10% (2 of 21) of women
who only received intrapartum ARV.
There were 4 transmission events, with
4 infants identified as HIV infected
during the18-monthperiod: 2 inThailand,
2 in Africa (HIV-1 transmission rate: 1.8%;
95% CI, 0.048%–3.6%). All transmissions
occurred in infants born to women who
received antepartum ZDV throughout
pregnancy and/or intrapartum ARV. One
infant in Thailand had documented in
utero transmission with a positive HIV-1
DNA PCR in the first day of life. Another
Thai infant had sequentially negative
HIV-1 DNA PCR results until 12 weeks but
a positive antibody result at 12 months
with retrospective RNA PCR testing
showing transmission between 12 and
24 weeks of age. A third infant had late
postnatal transmission with first posi-
tive HIV-1 RNA PCR at 9 months. One
breastfed infant had positive antibody
results at 19 months of age despite
negative HIV-1 RNA PCR results to 12
months. Three of 4 infants were infected
in the late postnatal period when
mothers were no longer receiving ARVs
througha study interventionwhen trans-
mission occurred. Ninety-four percent of
infants (n = 222) were not HIV-1 infected.
Of 14 infants who died or were lost to
follow-up, HIV-1 infection was indeter-
minate in 7. Of 6 breastfed infants lost
to follow-up before 18 months, none
had laboratory evidence of HIV-1 in-
fection at the last visit. HIV-1–free sur-
vival was 98.7% (95% CI, 97.3%–99.9%)
at 6 months and 96.4% (95% CI, 94.0%–
98.9%) at 18 months.
Eighty-six percent of infants (n = 202)
had a birth weight .2.5 kg and 10%
(n = 24) were between 1.5 and 2.5 kg.
Birth weight was not recorded in 4%.
Seventy-seven percent of infants were
born at term ($37 weeks’ gestation),
8% had a gestational age between 32
and 37 weeks, and for 15% gestational
age was not recorded. No statistically
significant differences in birth weight
or gestational agewere observed based
on maternal ARV regimen, viral load,
CD4 cell count, infant’s ARV regimen, or
place of birth (P . .5). In utero de-
velopment was adequate in 76% of
infants, categorized as appropriate for
gestational age. Ten infants were clas-
sified as small for gestational age, and
10 as large for gestational age (4%
each), with classification not performed
in 14%. Three (1%) additional infants
were classified as having intrauterine
growth retardation. No statistically sig-
nificant associations were observed
between intrauterine growth para-
meters and maternal ARV, infant’s ARV,
or maternal viral load or CD4 cell count.
All infants with intrauterine growth re-
tardation classification were from India,
and all infants in the large for gestational
age category were Thai. Apgar scores
were $7 at 1 minute in 94% and in all
infants by 5 minutes. No statistically
significant associations were observed
between Apgar scores and maternal
parameters (P . .20).
A high proportion of surgical deliveries
occurred: 53% of infants were born by
spontaneous vaginal delivery, 45% by
cesarean section, and 2% by forceps/
vacuum extraction. Cesarean sections
were performed for delivery of all Indian
infants (n = 47), 38% of Thai infants (n =
58), and in 1 (3%) of 36 African deliveries.
This reflects a difference in approach to
mode of delivery by setting and was
statistically significant (P , .001). No
statistically significant associations
TABLE 2 Subject Enrollment Into A5190/P1054 per Parent Protocol and Participating Country
Maternal Perinatal Studies for PMTCT, n Maternal ARV Treatment Studies, n
P1032 A5207 A5175 A5208 HPTN 052 Total
Thailand 151 — 1 — — 152 (64%)
India — 46 1 — — 47 (20%)
Malawi — 15 2 — 8 25 (11%)
Zimbabwe — — 3 — 3 6 (3%)
South Africa — — 1 3 1 5 (2%)
Brazil — — — — 1 1 (0.4%)
—, no enrollments.
TABLE 3 Fetal Exposure to Maternal ARVs and Direct Infant Exposure to ARV in A5190/P1054
Maternal ARV N = 236 % Direct Infant ARV Exposure N = 236 %
$3 ARVa 24 10 NVP only 31 13
$7 d ZDVb 191 81 ZDV/sd-NVP 200 85
Intrapartum only 21 9 ZDV only 5 2
sd-NVP, single dose NVP.
a Thirteen women continued triple ARV while breastfeeding.
b Twelve women received triple ARVs in the first trimester of pregnancy.
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were observed between mode of de-
livery and maternal viral load, CD4 cell
count, or ARV use. The vast majority of
deliveries occurred in hospital settings
(97%), and all 8 nonhospital deliveries
occurred in Africa. Twenty-six percent of
deliveries in Malawi and Zimbabwe
were in nonhospital settings.
In the first 6 months, 23 infants had
at least 1 hospitalization, and 3 had$2
admissions (11% hospitalization). By
18months, 36 infantswere hospitalized
once, and 11 had$2 admissions (20%
hospitalization). The median duration
of hospitalization was 5 days (range, 2–
51 days). The majority occurred in un-
infected infants for common childhood
illnesses, (respiratory/gastrointestinal
infections). Hospitalizations did not vary
by geographic area: 11% in Africa, 17%
in India, and 23% in Thailand (P = .25).
Median weight, height, head circum-
ferenceandcorresponding z scoresare
detailed in Fig 1. There were significant
differences by geographic region for
weight, weight-for-age z scores (WAZ),
height, and height-for-age z scores
(HAZ) at all time points, as well as head
circumference up to 9 months of age
and head-circumference-for-age z scores
up to 6 months of age. Infants in India
(nonbreastfed) had the lowest or second
lowest median weights at all time points.
Nonbreastfed infants in Africa had the
largest median weight. Weight differ-
enceswere observed at later time points
(ages 9, 12, and 18 months). Specifically,
African infants had lowermedianweights
and WAZ after the first 6 months of life,
and most were exposed in utero to$3
ARV drugs. Statistically significant dif-
ferences by maternal viral load were
observed at 3 months in infant length
and HAZ (but not weight or WAZ) (P =
.014, P = .007, respectively), 6 months
for HAZ (P = .044), and 18 months for
both parameters (P = .032, P = .02). The
5 infants born to mothers with $100
000 copies/mL RNA had the shortest
stature and HAZ within the cohort.
Throughout the first 18 months of life,
89 (38%) infants had $1 grade 3 or 4
serious adverse event (SAE) (Table 4).
The most common laboratory abnor-
mality was hematologic, primarily ane-
mia (13%). Abnormal chemistries were
primarily due to high potassium lev-
els in infancy (8%), without clinical
repercussions. Abnormal liver function
findings were primarily due to hyper-
bilirubinemia in the neonatal period
(4%) or transaminase elevations (5%).
FIGURE 1
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By maternal ARV exposure, serious
adverse event (grades 3–5) rates were
38% in triple ARV–exposed infants (9 of
24), 35% in ZDV-exposed infants (67 of
191), and 62% in intrapartum-only ARV-
exposed infants (13 of 21) (P = .01). No
statistically significant differences in
grades 3 to 5 adverse events by geog-
raphy, maternal CD4 cell count, or ma-
ternal viral load were observed.
Neonatal medical conditions were
present in 30% of infants (n = 70), as
shown in Table 4, (39% of Thai, 17% of
Indian, and 6% of African infants).
Beyond the neonatal period, clinical
conditions were frequently diagnosed
(Table 4). Sixty-seven percent of Thai
infants had $1 event in the newborn
period and 84% had events beyond this
period. Thai infants constituted 64% of
the patient cohort, and all were in the
ZDV-in-pregnancy-arm receiving ZDV/
single-dose NVP in the neonatal period.
Reporting of $1 clinical diagnosis var-
ied geographically: 84% of infants in
Thailand, 31% in Africa, and 9% in India.
Congenital abnormalities/inborn errors
ofmetabolism (n = 24) were reported in
18 (7.6%) children as shown in Table 4.
Except for 1 case of hydrocele, all were
Thai infants (11%; 95% CI, 6.7%–17%).
None of the infants with congenital
defects had first-trimester exposure to
maternal ARV. No significant associa-
tions with maternal CD4 or viral load
were observed.
Four deaths occurred (1.8%; 95% CI,
0.05%–3.49%): 3 infants in Africa
from gastroenteritis, pneumonia, and
pneumonia/malnutrition. The remaining
death was in Thailand, in an 8-week-old
infantwith trisomy21 and cardiacdefects
with aspiration pneumonia. All infants
who died had negative HIV-1 DNA PCRs.
DISCUSSION
A5190/P1054 was designed to monitor
pregnancy and infant outcomes in sub-
jects participating in NIH-sponsored in-
ternational trials that used ARV for
maternal treatment or PMTCT purposes.
It accompanied the debut of a large in-
ternational initiative by the NIH with
the release of multiple ARV trials in the
early to mid-2000s. The present analysis
focusedon infant outcomes inaprotocol
endorsed by the ACTG, HPTN, and IMPAACT
networks. A5190/P1054 demonstrated
the feasibility of extended monitoring
of HIV-exposed infants up to 18 months
of age in settings where clinical trials
infrastructure is in place and trained
medical staff are available for recog-
nition of clinical events. Although a
relatively high percentage of eligible
infants was enrolled while parent
studies and the current study were
enrolling simultaneously (∼85%, data
not shown), the absolute number of
subjects participating in the current
study was relatively small. Enrollment
of mother/infant pairs in observational
studies, particularly internationally,
can pose a challenge, especially when
participating sites are not inherently
affiliated with pediatric networks. Syn-
chronization of maternal and infant
visits can be difficult, as clinics might
have different locations or schedules,
complicating transportation and logis-
tics. Enrollment from adult sites was
initially slower, but the challenge was
overcome once pediatric providers
were incorporated by sites for perfor-
mance of study visits. In a time of com-
peting priorities and budget restraints,
observational safety studies with long-
term follow-up are not as competitive
for funding as intervention studies.
Nevertheless, it was shown through this
endeavor that clinical trial sites in di-
verse settings are capable of effectively
managing children of women enrolled
in research protocols. Careful clinical
monitoring demonstrated that in HIV-
exposed, uninfected infants, conditions
requiring medical attention were not
infrequent, but long-lasting clinical re-
percussions were rare.
The vast majority of subjects (95%) did
not have first-trimester exposure to
maternal ARV; therefore, the study
did not assess the safety of triple ARV
during embryogenesis. However, no
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between later maternal exposure to
ARV, particularly ZDV and intrapartum
single-dose NVP plus 2 or 3 other ARVs,
and SAEs. Postpartum ARV exposure
was rare as only 12% of infants were
breastfed. Findings were reflective of
the natural history of HIV exposure in
infants who received maternal ARV in
later months of intrauterine life.
One critical finding was the excellent
HIV-free survival observed at 18months
of age. Intrapartum HIV-1 transmission
was not noted, as 1 infant had diagnosed
in utero infection, and the remaining
3 infants had late postpartum HIV
acquisition, long after PMTCT inter-
ventions were completed. Although
women with lower CD4 cell counts are
at higher risk of HIV-1 mother-to-child
transmission, transmitting mothers
had higher cell numbers and came
from perinatal studies evaluating tail-
end ARV regimens for prevention of
NVP resistance. None of the 24 mothers
receiving multiple ARV for treatment
purposes transmitted HIV-1 (92% had
viral loads ,1000 copies/mL). Mode of
delivery reflected country practices
with a high cesarean section rate of
45% which could also explain no intra-
partum HIV transmission. Most deliver-
ies were hospital based, including 74%
of deliveries in Malawi and Zimbabwe.
This likely reflected the participation of
clinical trial sites with greater resour-
ces, increased surveillance, and greater
patient access to care. Infant mortality
was not associated with HIV status.
Birth and neonatal parameters were
within normal limits and varied by geo-
graphic region. Indian infants had the
lowest growth parameters in the first
months of life, while Thai infants had
significantly higher WAZ and HAZ in the
first months, as did African infants. How-
ever, at later time points, infants born in
Africa had the lowest growth parameters
(negative WAZ and HAZ), consistent with
weaning practices in the second or third
semesters of life, a phenomenon ob-
served in breastfeeding studies.11–14 One
interesting finding was the association
between higher maternal viral load and
shorter infant stature at 3, 6, and 18
months. Studies have demonstrated a
positive association between maternal
health and infant outcomes as late as 12
months of age.15–17 The potential associa-
tion between maternal viremia and infant
stunting deserves further investigation.
The relatively large number of reported
adverse events was likely due to in-
creased study surveillance. Likewise,
amuch largerproportionof Thai infants
TABLE 4 SAEs Grade 3 or 4 (Requiring Medical Attention), Most Common Clinical Events in the
Neonatal Period and Beyond, and Congenital Defects/Inborn Errors of Metabolism
SAEs Grade 3 or 4
No. of Subjects % of Subjects (N = 236)
Laboratory: hematologic SAEs 38 16
Laboratory: blood chemistry SAEs 24 10
Laboratory: liver/hepatic SAEs 14 6
Clinical: gastrointestinal SAEs 9 4
Clinical: respiratory SAEs 9 4
Total subjects with SAEsa 89 38
Neonatal conditions
Hematologic disordersb 23 10
Infections/infestations 17 7
Pregnancy/puerperium/perinatal disorders 11 5
Respiratory, thoracic mediastinal disorders 8 3
Eye disorders 8 3
Metabolism/nutrition disorders 6 3
Skin/soft tissue disorders 5 2
Total neonatal conditions 70 30
Conditions beyond neonatal periodc
Respiratory infections 107 45
Gastrointestinal infections 52 22
Hematologic disorders 42 18
Systemic viral infections 24 10
Allergic/autoimmune diseases 22 9
Skin and tissue infections 20 8
Congenital abnormalities/inborn errors metabolism
(18 subjects)
Urinary/genital tract malformations 8 3
Hydrocele 5 —
Cryptorchism 1 —
Inguinal hernia 1 —
Pelvic-ureteric obstruction 1 —
Congenital heart defects 8 3
Ventricular septal defect 3 —
Patent ductus arteriosus 1 —
Congenital pulmonary artery stenosis 1 —
Congenital pulmonary hypertension 1 —
Complex congenital heart disease 1 —
Tetralogy of Fallot 1 —
Congenital hypothyroidism 2 1
Congenital lacrimal gland anomaly 1 1
Hypertelorism of orbit 1 1
Glucose-6-phosphate hydrogenase deficiency 2 1
Inborn error of bilirubin metabolism 1 1
Trisomy 21 1 1
Total number of conditions 24
Total number of events 398
Total number of subjects with events 144
—, percent figures not given for subcategories.
a Subjects may have .1 SAE.
b Anemia in 22 subjects.
c Conditions with ,3% frequency are not listed.
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had clinical diagnoses or adverse events
(84%) as opposed to Indian or African
infants, and they also had higher hospi-
talization rates. The reason why Thai
infants had relatively high rates of con-
genital malformations or inborn errors
of metabolism is unclear. Thai infants
were exposed to ZDV prophylaxis only in
later months of pregnancy. Congenital
malformation rates are reported at∼3%
to 6% in HIV-exposed infant cohorts18,19
but longer periods of observation tend
to uncover higher rates of conditions
unidentified at birth.20 One advantage
of prospectively managing HIV-exposed
infants is the opportunity for multiple
diagnostic evaluations, which enable
detection of clinical conditions, some-
thing that cannot be ascertained
through antiretroviral pregnancy regis-
tries, as these do not include follow-up
for infants. There were a number of SAEs
reported in this study that would require
additional follow-up time for evaluation
of clinical significance and/or potential
resolution as there is a paucity of data
on long-term pediatric outcomes. An-
other plausible explanation for the high
rate of congenital defects is increased
diagnostic capacity at selected sites,
which potentially could explain the
higher rate of findings observed in
Thailand. This underscores the need for
longitudinal data from HIV-exposed pe-
diatric populations, since comparative
population data are not available. Had
ARV exposures occurred within the first
trimester of pregnancy in the current
study, the higher rate of congenital mal-
formationsmight have been erroneously
associated with maternal ARV use. Lon-
ger periods of infant follow-up are
also necessary for identification of
potential mitochondrial dysfunction
or neurologic disorders.
A5190/P1054 did not uncover an as-
sociation between adverse events in
HIV-exposed infants and moderate ma-
ternal ARVexposure (95%women had no
first-trimesterARVexposureand90%had
notriple-ARVexposure),althoughalarger
cohort would be needed to evaluate
associations with lower frequency rates.
Data from this study, nevertheless, are
reassuring as they suggest that partici-
pationof pregnantpatients in ARVclinical
trials renders benefits to women and
their infants. Continued monitoring of
infant safety, however, is paramount as
unexpected outcomes after in utero ex-
posure to drugs might not be easily
recognizable.21 Infant safety data should
be systematically collected as our find-
ings document that this approach is
feasible and acceptable within the
network infrastructure. This approach
should be continued as novel ARVs are
made available through international
research initiatives.
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